KDR and neoplasm: Given the compelling results from previous clinical research, both camrelizumab (a selective humanized IgG4 (immunoglobulin G4) monoclonal antibody) and rivoceranib (also known as apatinib, a highly selective VEGFR-2 (vascular endothelial growth factor receptor (2) inhibitor) have exhibited notable efficacy in tumor management and controllable adverse reactions as second-line treatments for pretreated advanced HCC patients [10, 11].